Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes

NCT07392125 is registered in ClinicalTrials.gov with Achieve Life Sciences as lead sponsor.

NCT NCT07392125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07392125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes
Lead sponsor
Achieve Life Sciences
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 15, 2026
Completion date
September 30, 2027
Enrollment
800 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

vaping cessation